Related Experiment Videos
Angiotensin-converting enzyme inhibition in myocardial infarction--Part 1: Clinical data
V F Huckell1, V Bernstein, J A Cairns
1Vancouver Hospital, British Columbia. huckell@mindlink.bc.ca
The Canadian Journal of Cardiology
|February 1, 1997
Summary
Angiotensin-converting enzyme (ACE) inhibitors are effective for patients after myocardial infarction (MI). New evidence confirms their benefit when used within 24 hours of an acute MI, overcoming earlier concerns.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Clinical trial evidence supports angiotensin-converting enzyme (ACE) inhibitors for myocardial infarction (MI) management.
- Previous concerns regarding ACE inhibitor use in acute MI were based on early trial results.
Purpose of the Study:
- To review major clinical trials on ACE inhibitors in acute myocardial infarction.
- To discuss controversies and key issues surrounding ACE inhibitor use in the acute phase of MI.
Main Methods:
- Review of major clinical trials on ACE inhibitors.
- Analysis of data from large, randomized studies.
- Discussion from a Canadian National Opinion Leader Symposium.
Main Results:
- Recent large, randomized studies demonstrate the efficacy of ACE inhibitors in acute MI.
- Evidence supports the use of ACE inhibitors within the first 24 hours post-MI.
- New data alleviates previous concerns about ACE inhibitor safety in acute MI.
Conclusions:
- ACE inhibitors are beneficial in managing patients post-myocardial infarction.
- Early administration of ACE inhibitors (within 24 hours) is effective and safe.